|
|
News Breaks
|
October 8, 2009
|
| 08:45 EDT |  | ISPH |
| theflyonthewall.com: | Inspire Pharmaceuticals and Yamasa enter into license agreement | | Inspire Pharmaceuticals and Yamasa Corporation entered into a Technology License Agreement For The Manufacture of Denufosol with an effective date of September 25, 2009. Inspire is currently developing denufosol tetrasodium inhalation solution for the treatment of cystic fibrosis. During Inspire’s denufosol development program, Yamasa has manufactured all of the denufosol used by Inspire in its related clinical trials. The purpose of the Agreement is to facilitate the transfer of the current denufosol manufacturing technology, including intellectual property, to an additional manufacturer and thus enable a two-supplier strategy for denufosol. The manufacture and sale of denufosol is further protected in the United States under patents held by Inspire that have claims to the drug substance, the formulation, and method of use that expire in February 2017, subject to any applicable patent restoration. :theflyonthewall.com |
|
|
News For ISPH From The Last 14 Days Check below for free stories on ISPH the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
